- Home
- IVA
as 11-21-2024 4:00pm EST
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.
| Founded: | 2011 | Country: | France |
| Employees: | N/A | City: | N/A |
| Market Cap: | 117.3M | IPO Year: | 2020 |
| Target Price: | $14.00 | AVG Volume (30 days): | 28.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.53 - $4.75 | Next Earning Date: | 09-25-2024 |
| Revenue: | $20,652,523 | Revenue Growth: | -12.56% |
| Revenue Growth (this year): | -76.07% | Revenue Growth (next year): | 361.78% |
Latest Inventiva S.A. American Depository Shares News
IVA Breaking Stock News: Dive into IVA Ticker-Specific Updates for Smart Investing
GlobeNewswire
7 hours ago
Inventiva reports 2024 Third Quarter Financial Information¹
GlobeNewswire
a day ago
Statement of total voting rights and shares forming the company’s share capital as of November 4, 2024
GlobeNewswire
a day ago
Combined General Meeting of December 11, 2024 - Availability of the preparatory documents
Pharma Voice
4 days ago
The first MASH drug could open the door for others — including GLP-1s
GlobeNewswire
6 days ago
Inventiva will present data from the final analysis of the Phase 2 study evaluating the combination of lanifibranor with empagliflozin in patients with MASH and T2D at the AASLD The Liver Meeting® late-breaker session
GlobeNewswire
22 days ago
Inventiva announces the positive recommendation of the fifth DMC of the NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH
GlobeNewswire
a month ago
Inventiva announces a late breaker abstract from LEGEND, Phase 2 trial, evaluating lanifibranor in combination with empagliflozin in MASH at the AASLD The Liver Meeting® 2024
MT Newswires
a month ago
Top Premarket Decliners
Compare IVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "IVA Inventiva S.A. American Depository Shares - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.